T. Rowe Price Associates’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-44,200
| Closed | -$24K | – | 3106 |
|
|
2024
Q4 | $24K | Hold |
44,200
| – | – | ﹤0.01% | 2988 |
|
|
2024
Q3 | $78K | Hold |
44,200
| – | – | ﹤0.01% | 2866 |
|
|
2024
Q2 | $52K | Buy |
44,200
+13,271
| +43% | +$33.2K | ﹤0.01% | 2850 |
|
|
2024
Q1 | $280K | Buy |
30,929
+2,624
| +9% | +$25.5K | ﹤0.01% | 2466 |
|
|
2023
Q4 | $308K | Buy |
28,305
+936
| +3% | +$7.01K | ﹤0.01% | 2364 |
|
|
2023
Q3 | $221K | Buy |
27,369
+1,571
| +6% | +$13.1K | ﹤0.01% | 2467 |
|
|
2023
Q2 | $281K | Buy |
25,798
+6,098
| +31% | +$52.2K | ﹤0.01% | 2394 |
|
|
2023
Q1 | $136K | Sell |
19,700
-3,400
| -15% | -$21.3K | ﹤0.01% | 2623 |
|
|
2022
Q4 | $92K | Buy |
23,100
+7,500
| +48% | +$36.9K | ﹤0.01% | 2736 |
|
|
2022
Q3 | $104K | Hold |
15,600
| – | – | ﹤0.01% | 2718 |
|
|
2022
Q2 | $76K | Buy |
15,600
+4,417
| +39% | +$26.9K | ﹤0.01% | 2811 |
|
|
2022
Q1 | $105K | Buy |
+11,183
| New | +$111K | ﹤0.01% | 2837 |
|
|
2021
Q2 | – | Sell |
-42,186
| Closed | -$653K | – | 2960 |
|
|
2021
Q1 | $653K | Buy |
+42,186
| New | +$610K | ﹤0.01% | 2238 |
|
|
2018
Q4 | – | Sell |
-102,165
| Closed | -$4.09M | – | 2600 |
|
|
2018
Q3 | $4.09M | Buy |
+102,165
| New | +$2.91M | ﹤0.01% | 1479 |
|
|
2018
Q1 | – | Sell |
-104,075
| Closed | -$3.4M | – | 2594 |
|
|
2017
Q4 | $3.4M | Buy |
+104,075
| New | +$2.8M | ﹤0.01% | 1477 |
|
T. Rowe Price Associates's MRNS Position: Q1 2025 in Review
T. Rowe Price Associates sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 44,200 shares — an estimated $24K sold.
T. Rowe Price Associates first reported a position in MRNS in Q4 2017 and held it in 15 quarters. The position peaked at $4.09M in Q3 2018. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- T. Rowe Price Associates reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 44,200 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $24K.
- T. Rowe Price Associates first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 15 quarters.
- T. Rowe Price Associates's Marinus Pharmaceuticals, Inc position peaked at $4.09M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.